| Dasatinib MonohydrateInhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.56%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Dasatinib Monohydrate Dilution Calculator
calculate
Dasatinib Monohydrate Molarity Calculator
calculate
| Cas No. | 863127-77-9 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | (Z)-N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carbimidic acid hydrate | ||
| Canonical SMILES | CC1=C(/N=C(O)/C(S2)=CN=C2NC3=CC(N4CCN(CCO)CC4)=NC(C)=N3)C(Cl)=CC=C1.O | ||
| Formula | C22H28ClN7O3S | M.Wt | 506.02 |
| Solubility | ≥25.3mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Description:
IC50: 0.55 and 3.0 nM for Src and Bcr-Abl tyrosine kinases, respectively
Chronic Myeloid Leukemia (CML) is a disease characterized by the presence of the Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, that is present in >90% of the patients. Dasatinib (BMS-354825) is a novel, potent, and multitargeted kinase inhibitor that targets ABL, SRC, KIT, PDGFR, and other tyrosine kinases.
In vitro: Dasatinib is a potent ATP-competitive inhibitor in biochemical assays with broad-spectrum antiproliferative activities against hematological and solid tumor cell lines. Dasatinib was more potent than imatinib at inhibiting nonmutated BCR-ABL kinase activity. In addition, the kinase activity of 14 out of 15 different clinically relevant, imatinib-resistant BCR-ABL isoforms was successfully inhibited [1].
In vivo: Mice were dosed with Dasatinib or vehicle alone by gavage for 2 weeks, beginning 3 days after injection of Ba/F3 cells. All vehicle-treated mice developed progressive disease. In contrast, Dasatinib–treated mice harboring nonmutant BCR-ABL or the clinically common imatinib-resistant mutation M351T appeared healthy with no evidence of weight loss, lethargy, or ruffled fur and showed more than one log lower levels of bioluminescent activity after 2 weeks of therapy [2].
Clinical trial: Dasatinib has been evaluated in clinical trials in adult patients with Ph-positive leukemias after imatinib failure or intolerance when it was proven to be effective in the chronic, accelerated and blast phases of CML. It was approved by FDA in 2006 for the treatment of CML in the three phases and also for Ph-positive ALL [2].
Reference:[1] Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401.[2] Monika Conchon, Carla Maria Boquimpani de Moura Freitas, Maria Aparecida do Carmo Rego, and José Wilson Ramos Braga Junior. Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia Rev Bras Hematol Hemoter. 2011; 33(2): 131–139.
